bioAffinity Technologies Inc (NASDAQ: BIAF) stock falls in Monday premarket. Investors weigh 2025 revenue declines against surging CyPath Lung sales.
bioAffinity Technologies Stock Cools Off After Strong Friday Rally – Here’s Why
Importance Rank:
1